Disc Medicine, Inc. (IRON) vs Supernus Pharmaceuticals, Inc. (SUPN)
A side-by-side comparison of Disc Medicine, Inc. and Supernus Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IRON
Disc Medicine, Inc.
$62.99HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
SUPN
Supernus Pharmaceuticals, Inc.
$42.11HealthcareDelayed quote: Oct 6, 2026, 2:15 PM EDT
Total return — IRON vs SUPN
growth of $100 · dividends reinvested · last 6yIRON -38.5% (-7.8%/yr)SUPN +83.4% (+10.6%/yr)SUPN compounded faster over this window
IRON SUPN
IRON vs SUPN: by the numbers
- •SUPN is the larger company ($2.44B vs $2.42B market cap).
- •Both run net losses; IRON's is the smaller (0.00% vs -13.23% net margin).
Metrics side by side
Valuation
| Metric | IRON | SUPN |
|---|---|---|
| Forward P/E | N/A | 16.42 |
| P/S ratio | N/A | 2.94 |
| P/B ratio | 3.75 | 2.37 |
| FCF yield | N/A | 0.77% |
Profitability
| Metric | IRON | SUPN |
|---|---|---|
| Gross margin | 0.00% | 88.07% |
| Operating margin | 0.00% | -5.13% |
| Net margin | 0.00% | -13.23% |
| ROE | -38.17% | -10.66% |
| ROIC | -38.21% | -10.24% |
Growth (annualized)
| Metric | IRON | SUPN |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 7.78% |
| FCF CAGR (5Y) | N/A | -30.77% |
| Total return CAGR (5Y) | 10.70% | 9.85% |
Frequently asked
- How have IRON and SUPN total returns compared?
- Over the past 5 years, IRON delivered 10.70% and SUPN delivered 9.85% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.